KALA BIO completes patient enrollment in CHASE trial, evaluating KPI-012 for treating persistent corneal epithelial defect, with results due Q3 2025. KALA BIO, Inc. announced the completion of patient ...
In this figure you can see all of the diseases that were identified linked to epithelial barrier defect and microbial dysbiosis linked to epithelial barrier damaging environmental substances In this ...
Transplanted autologous corneal stem cells successfully repaired corneal injuries in patients. Over 90% of patients achieved complete or partial success. The procedure proved safe with no serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback